Ei­sai cut­ting 91 jobs af­ter out-li­cense deal; Mer­ck touts first-line Keytru­da re­sults in en­dome­tri­al can­cer

Ei­sai will elim­i­nate 91 af­ter it out-li­censed a seizure drug.

An Ei­sai spokesper­son told End­points News that the change-up is tied to Fy­compa, a seizure treat­ment that Flori­da rare dis­ease biotech Cat­a­lyst Phar­ma­ceu­ti­cals agreed to pay $160 mil­lion to Ei­sai in ex­change for com­mer­cial rights back in De­cem­ber. The job cuts were orig­i­nal­ly flagged in a New Jer­sey state WARN no­tice.

The spokesper­son said that Cat­a­lyst in­di­cat­ed in­ter­est in re­tain­ing up to 40 em­ploy­ees who work on Fy­compa. Those who qual­i­fy will have an op­por­tu­ni­ty to in­ter­view with Cat­a­lyst.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Venture & Research Associate

Alexandria Real Estate Equities

San Francisco, CA, USA